ARCELLX, INC. ACLX 深 沪
已收盘 12-12 16:00:00 美东时间
71.86
-0.830
-1.14%
华盛通- 最 高73.94
- 今 开72.93
- 成交量 71.35万股
- 最 低 71.09
- 昨 收 72.69
- 总市值 39.85亿
- 52周最高 94.07
- 市盈率 静 --
- 换手率 1.29%
- 52周最低 47.8601
- 委 比 -69.49%
- 总股本 5545.89万
- 历史最高 107.3699
- 量 比 0.39
- 振 幅 3.92%
- 历史最低 6.035
- 每 手 1
- 风险率 8.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Why Is Arcellx Stock Surging Today?
Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.
12-09 02:23
Needham Reiterates Buy on Arcellx, Maintains $105 Price Target
Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $105 price target.
12-08 18:39
Reported Saturday, Anito-Cel Demonstrates 96% ORR And 74% CR/sCR In iMMagine-1 Relapsed/Refractory Multiple Myeloma, Supporting Planned 2026 Commercial Launch
Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time --Overall MRD negativity was 95% and sustained MRD negativity for >6 months was 83%, both at
12-08 16:47
Wolfe Research Initiates Coverage On Arcellx with Peer Perform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Arcellx (NASDAQ:ACLX) with a Peer Perform rating.
11-19 01:17
Arcellx Q3 EPS $(0.99) Beats $(1.03) Estimate, Sales $4.949M Miss $9.639M Estimate
Arcellx (NASDAQ:ACLX) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.03) by 4.26 percent. This is a 106.25 percent decrease over losses of $(0.48) per share from the same
11-06 06:29
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Canaccord Genuity Maintains Buy on Arcellx, Raises Price Target to $130
Canaccord Genuity analyst John Newman maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $121 to $130.
11-03 21:25
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Stifel Reinstates Buy on Arcellx, Announces $129 Price Target
Stifel analyst Stephen Willey reinstates Arcellx (NASDAQ:ACLX) with a Buy and announces $129 price target.
10-16 21:52
